华北制药(600812.SH)：下属公司头孢丙烯片获得《药品注册证书》

Core Viewpoint - North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., has received the drug registration certificate for Cefprozil tablets (0.25g) from the National Medical Products Administration, marking a significant development in its antibiotic portfolio [1] Group 1: Product Approval - The drug Cefprozil is classified as a second-generation cephalosporin antibiotic [1] - The approved indications for Cefprozil in China include treatment for mild to moderate infections caused by sensitive bacteria, such as upper respiratory infections, lower respiratory infections, and skin and soft tissue infections [1] Group 2: Indications - Specific approved indications include: 1. Upper respiratory infections: Streptococcal pharyngitis/tonsillitis, otitis media, and acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 2. Lower respiratory infections: Acute bronchitis and exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] 3. Skin and soft tissue infections: Non-complicated infections caused by Staphylococcus aureus and Streptococcus pyogenes, with the note that abscesses may require surgical drainage [1]